Street Calls of the Week
Director Thomas G. Wiggans of Jasper Therapeutics, Inc. (NASDAQ:JSPR) acquired 41,000 shares of Voting Common Stock at $2.43 per share on September 22, 2025, near the stock’s 52-week low of $2.27. The $99,630 purchase comes as the stock has declined 89% over the past year, with the company’s market cap now at $38 million. According to InvestingPro analysis, JSPR appears undervalued at current levels.
The shares were bought indirectly through the Wiggans Living Trust. Wiggans also acquired 41,000 Common Stock Warrants (right to buy) indirectly through the Wiggans Living Trust.
Following the transaction, Wiggans indirectly holds 41,000 shares through the Wiggans Living Trust, and directly holds 5,000 shares.
In other recent news, Jasper Therapeutics has announced a public offering expected to raise approximately $30 million in gross proceeds. The offering includes 11,670,707 shares of common stock with accompanying warrants and 675,000 pre-funded warrants, with common warrants exercisable at $2.92 per share starting six months after issuance. This development comes as part of the company’s strategy to advance the development of briquilimab, its antibody therapy for mast cell-driven diseases. Following this announcement, both JMP Securities and BTIG adjusted their price targets for Jasper Therapeutics. JMP Securities lowered its price target to $6 from $12, citing significant dilution from the public offering, while maintaining a Market Outperform rating. Similarly, BTIG reduced its price target to $7 from $20, maintaining a Buy rating on the stock. These adjustments reflect the financial implications of the recent $30 million capital raise and ongoing investigations into a faulty drug lot for briquilimab.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.